CBO scores drug pricing reform as budget-neutral by Q1 2027
user-generated· macro
CBO scores drug pricing reform as budget-neutral by Q1 2027
Market overview
The Congressional Budget Office is expected to evaluate the reform’s fiscal impact as neutral or positive, reducing political opposition. This outcome will depend on finalized bill details and CBO’s scoring methodology.
macro prediction market
- Implied probability (Yes)
- 68%
Source: user-generated
More macro markets
- 10-year Treasury yield exceeds 5% by Q4 2026 due to Fed oversight — 67% Yes
- Ukraine aid funding drops 20% in next federal budget cycle — 70% Yes
- US new business filings surpass 2026 record by 2027 — 75% Yes
- Fed holds interest rates steady through 2026 due to labor stability — 70% Yes
- Fed cuts rates within 6 months under Warsh — 70% Yes
- AI boosts oil production by 5%+ by 2027 — 70% Yes
- U.S. energy production hits new annual record in 2026 — 80% Yes
- Trump's approval rating drops below 40% by year-end — 70% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…